Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124730833 | 12473083 | 3 | F | 20110207 | 20160919 | 20160616 | 20160921 | EXP | NL-PFIZER INC-2015302594 | PFIZER | 60.00 | YR | M | Y | 0.00000 | 20160921 | OT | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124730833 | 12473083 | 1 | PS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | UNK | U | 21106 | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||||
| 124730833 | 12473083 | 2 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 2X/WEEK | U | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | BIW | |||||
| 124730833 | 12473083 | 3 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 1X/WEEK | U | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 4 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 30 MG, 3X/WEEK | U | 21106 | 30 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||
| 124730833 | 12473083 | 5 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 90 MG, 1X/WEEK | U | 21106 | 90 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 6 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 120 MG, 1X/WEEK | U | 21106 | 120 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 7 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 50 MG, 1X/WEEK (ON SUNDAY) | U | M61752 | 21106 | 50 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||
| 124730833 | 12473083 | 8 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 40 MG, 1X/WEEK (ON SUNDAY) | U | 21106 | 40 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 9 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 30 MG, 1X/WEEK | U | 21106 | 30 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 10 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 60 MG, 1X/WEEK | U | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||
| 124730833 | 12473083 | 11 | SS | SOMAVERT | PEGVISOMANT | 1 | 80 MG, 2X/WEEK | U | 21106 | 80 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | BIW | ||||||
| 124730833 | 12473083 | 12 | C | SOMATULINE DEPOT | LANREOTIDE ACETATE | 1 | 120 MG, 1X/28 DAYS | 0 | 120 | MG | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124730833 | 12473083 | 1 | Acromegaly |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124730833 | 12473083 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124730833 | 12473083 | Blood glucose increased | |
| 124730833 | 12473083 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124730833 | 12473083 | 1 | 20110207 | 0 | ||
| 124730833 | 12473083 | 2 | 20120703 | 0 | ||
| 124730833 | 12473083 | 3 | 20151008 | 0 | ||
| 124730833 | 12473083 | 4 | 20160411 | 0 | ||
| 124730833 | 12473083 | 5 | 20160530 | 0 |